254 related articles for article (PubMed ID: 24428792)
1. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
3. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
4. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
5. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
6. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
[No Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
8. Current and future trends in treatment of severe retinopathy of prematurity.
Wallace DK; Wu KY
Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
[TBL] [Abstract][Full Text] [Related]
9. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
[TBL] [Abstract][Full Text] [Related]
10. Confluent diode laser coagulation: the gold standard of therapy for retinopathy of prematurity.
Prepiaková Z; Tomcíková D; Kostolná B; Gerinec A
J Pediatr Ophthalmol Strabismus; 2015; 52(1):43-51. PubMed ID: 25643370
[TBL] [Abstract][Full Text] [Related]
11. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial.
Mintz-Hittner HA
Eur J Ophthalmol; 2012; 22(5):685-6. PubMed ID: 22669847
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
Isaac M; Mireskandari K; Tehrani N
J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for retinopathy of prematurity.
Gilbert CE; Zin A; Darlow B
N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
[No Abstract] [Full Text] [Related]
16. Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.
Chen W; Binenbaum G; Karp K; Baumritter A; Pearson DJ; Maguire AM; Quinn GE
J AAPOS; 2014 Aug; 18(4):402-4. PubMed ID: 25087645
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for retinopathy of prematurity.
Lim LS; Mitchell P; Wong TY
N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
[No Abstract] [Full Text] [Related]
18. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
Flavahan PW; Lavy TE; Wykes W
Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.
Autrata R; Krejcírová I; Senková K; Holoušová M; Doležel Z; Borek I
Eur J Ophthalmol; 2012; 22(5):687-94. PubMed ID: 22669848
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
Ehmann D; Greve M
Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]